Second Phase III Study Of Avastin(R) (Bevacizumab) In 1st Line Metastatic Breast Cancer Meets Its Primary Endpoint
Roche announced that a phase III study in metastatic breast cancer investigating Avastin (bevacizumab) in combination with docetaxel chemotherapy compared to docetaxel alone, met its primary endpoint of improving the instance patients live without their disease advancing. The findings come
Original post by Women’s Health / Gynecology News From Medical News Today
Related Articles
Second Phase III Study Of Avastin In 1st Line Metastatic Breast Cancer Meets Its Primary Endpoint AVADO Study Of Avastin Plus Docetaxel Chemotherapy Showed Improved Progression-Free Survival In Patients With Advanced Breast Cancer Wyeth Initiates INTORACT — A New Clinical Trial To Examine TORISEL Plus Avastin For First-Line Treatment Of Advanced Kidney Cancer Solvent-Free Abraxane(R) Combined With Targeted Therapy Bevacizumab Evaluated As First-Line Treatment For Metastatic Breast Cancer Combination Therapy Of Solvent-Free Abraxane(R) And The Targeted Therapy Bevacizumab Evaluated As First-Line Treatment For Metastatic Breast Cancer
